The Imaging Research Core Facility provides researchers with the state-of-the art facilities and services for in vivo imaging. The facility provides cancer researchers its extensive imaging research infrastructure and expertise of -15 imaging faculty in Radiology and Biomedical Engineering to enhance and expand their ongoing research efforts. The advent of dedicated small animal imaging systems allows the integration of in vivo physiologic measurements with microscopic measurements of structural and cellular activities. The collaborative, multi-disciplinary approach provides a wealth of new information in elucidating the complex relationship between structure, genetics, replication, and function in genetically manipulated animal models of disease that have been used widely in cancer research with grounding in cellular/molecular-level understanding. The Imaging Research Core Facility is the centerpiece of the Case Center for Imaging Research which encompasses all aspects of the much broader imaging research program at Case/UHC. This includes molecular imaging, small animal imaging, and clinical imaging thrusts. Many of these thrusts are directly tied to the Case Comprehensive Cancer Center (Case CCC). The Imaging Research Core Facility's molecular and small animal imaging services, technologies, and research programs are described in detail below. Clinical imaging research programs are described in more detail in the Program 7: Developmental Therapeutics proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-21
Application #
8103086
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
21
Fiscal Year
2010
Total Cost
$225,289
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279
Bosca, Federica; Bielecki, Peter A; Exner, Agata A et al. (2018) Porphyrin-Loaded Pluronic Nanobubbles: A New US-Activated Agent for Future Theranostic Applications. Bioconjug Chem 29:234-240
Benson, Bryan L; Li, Lucy; Myers, Jay T et al. (2018) Biomimetic post-capillary venule expansions for leukocyte adhesion studies. Sci Rep 8:9328

Showing the most recent 10 out of 1227 publications